miRNA Biomarkers in Multiple Sclerosis

University of Gaziantep

Status

Completed

Conditions

Epigenetic

miRNA

Multiple Sclerosis

Biomarker

Treatments

Genetic: miRNA

Study type

Observational

Funder types

Other

Identifiers

NCT04772495

2015/7

Details and patient eligibility

About

Multiple Sclerosis (MS) characterized by demyelination and axonal degeneration is a chronic inflammatory disease of the central nervous system (CNS). Recent studies have shown that dysregulated miRNAs alter immune responses, so they may have roles basis on various genetic diseases such as MS and may be potential targets for biomarkers and new therapeutic approaches. In this study, we evaluated the dysregulation of miRNA expression levels at MS and MS stages. We also discussed the potential of these miRNAs to be biomarkers and/or therapeutic targets in MS.

Enrollment

69 patients

Sex

All

Ages

25+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

The age of 25 years and above
at least one Central Nervous System (CNS) demyelination event

Exclusion criteria

with genetic diseases, hypertension, head trauma, neuropsychiatric disease, diabetes mellitus, hypertension, cardiac failure, hepatic failure, renal failure, Thalassemia, Sickle cell disease, iron deficiency, and B12 deficiency